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and projected vials. Upper boundary was inﬂ uenced more by total target patients, 
response rate, and expected price with no risk sharing. CONCLUSIONS: The concept 
of performance-based payment is a risk sharing between the payer and manufacturer 
for high-quality of new agent, and improves to patient’s quality of life within the 
available national health-care budget. We show that the range of affordable price is 
calculated by a manufacturer’s proﬁ t and neutral point of health-care budget in the 
performance-based risk sharing and discuss potential challenges. 
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OBJECTIVES: To control the high pharmaceutical expenditure, the Bureau of 
National Health Insurance introduced the generic grouping method to reduce price 
variation among off-patent drugs since 2000. The purpose of this study was to 
examine the effect of the price adjustments on the trend of pharmaceutical expendi-
ture. METHODS: We used BNHI monthly claim data from 1999 to 2007 and 
incorporated drug registry ﬁ le, drug price ﬁ le and 2009 WHO ATC/DDD ﬁ le. To 
further analyze the effect of generic grouping, we classiﬁ ed the branded drug into three 
categories patented branded drug, off-patent branded drug with no competitive 
generic drug and off-patent branded drug with competitive drug. RESULTS: We found 
that from 1999 to 2007, the annual growth rate of pharmaceutical expenditure was 
6.0%; outpatient 6.3% and inpatient 5.5%. During the study period, the sales of the 
patented branded drugs rose from 20.5% to 30.9% with the highest increasing rate. 
The sales of the off-patent branded with competitive generic drugs and generic without 
the BA/BE testing drugs fell from 21.1% to 18.6% and from 39.3% to 28.4%, 
respectively. The sales volume in terms of DDD also has the same pattern as the drugs 
sales. Regarding the impact of drug price adjustment on Hospital, we found the share 
of drug claim by medical centers rose from 35.5% to 41.3%; regional hospitals from 
25.3% to 30.2%, however local hospitals and primary health care decreased their 
share. In terms of ﬁ rms, the IRPMA group held the highest increasing rate on share 
and importers held the lowest. CONCLUSIONS: The generic grouping price adjust-
ment policy has effectively reduced the off-patent branded drug expenditure. However, 
total drug expenditure didn’t decrease due to the increased expenditure of the new 
drugs with high prices. 
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OBJECTIVES: Radiopaque agents induce ADR frequently. But the numbers of ADR 
reporting are less than actual happening because of heavy workload on medical staffs. 
We created a simple and convenient online reporting system to replace paper report 
in our hospital. The aim of this study was to assess the variation of reporting rate. 
METHODS: In the system, the cases reported by physician including medication used, 
time of ADR come up and description of ADR event. We downloaded the data of 
patients who administrated radiopaque agents retrospectively as the base of study 
group, and observed the reporting rate of online reporting system from 2008 July to 
2009 June (i.e., intervention group), comparing it with the paper report in 2007. 
RESULTS: There are ﬁ ve radiopaque agents with four nonionic and 1 ionic contrast 
media (e.g., Gadobenate Dimeglumine, Iodixanol, Iohexol, Ioversol and Urograﬁ n) 
used in our hospital. We received 20 ADR reports within 22,754 prescriptions of 
radiopaque agents from January to December in 2007 and 62 ADR reports in 29,840 
prescriptions from 2008 July to 2009 June. The reporting rate elevated 2.3 times 
(0.09% to 0.21%) when we shifted paper reporting to online reporting system. In the 
intervention group, more than half ADR reports were rash and no serious side effects 
(e.g., nephrotoxicity, anaphylactic shock) had been reported. CONCLUSIONS: ADR 
report is important in patient safety and pharmacovigilance issues. In clinical practice, 
staff may miss to report ADR because of enormous amount of work load. If the 
reporting system is more user-friendly, it would be closer to the true incidence of 
adverse events which have been reported. 
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OBJECTIVES: Narcotic analgesic was usually used to relieve cancer pain in the past 
decades. Recently, co-analgesics with adjuvant drugs have become an essential way 
and successful alternatives for holistic care. The aim of this study is to assess the 
outcome of using cancer pain adjuvants. METHODS: This is an observational study. 
Cancer patients with pain score > 3 were recruited from three medical centers in 
Taiwan. Numeric Pain Rating Scale, Wong-Baker Face Pain Rating Scale and Brief 
Pain Inventory were used to evaluate the differences of pain control between two 
groups, addition of pain adjuvants and narcotics. The monthly consumption of narcot-
ics, the frequency of breakthrough pain and adverse event were recorded for analysis 
by Paired t-test. RESULTS: A total of 120 patients were eligible in this study. Fifty-ﬁ ve 
(45.8%) and 65 (54.2%) patients received narcotic analgesics and pain adjuvants for 
pain control, respectively. The satisfaction of patients in both groups on pain control 
improved 2.03 ± 1.87 points in the narcotics group and 2.14 ± 1.72 points in con-
comitant adjuvants group without signiﬁ cant difference. (F1,118 = 0.1024, P = 0.7495) 
The times of breakthrough pain was signiﬁ cantly decreased in adjuvants group as 
compared to narcotics group(−1.47 ± 2.23 vs. −0.48 ± 1.80; F1,118 = 7.3556, P = 
0.0077). CONCLUSIONS: No signiﬁ cant difference in total consumption of narcotics 
and pain control was founded. The frequency of breakthrough pain is likely to be 
improved in the concomitant adjuvants as compared in the narcotics group. The study 
found the safety of adjuvant therapy do no harm to palliative patients. 
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OBJECTIVES: Cholangiocarcinoma is a leading cause of cancer death in the North-
east of Thailand. Currently, chemotherapy and supportive care are the main treat-
ments in non-resectable cholangiocarcinoma patients. Many adverse events (AE) from 
disease and treatments have been reported that affect quality of life (QOL) of the 
patients. This study evaluated the efﬁ cacy of melatonin compared to placebo on the 
QOL, AE and survival time. METHODS: The study was a randomized, double-blind, 
placebo, controlled trial. The patients received treatment following the protocol of 
each hospital, and the study drug. Patients were randomized by mixed-block random-
ization stratiﬁ ed by hospital and type of treatment. The treatment group received 
melatonin (20 mg/day) and the control group received placebo. Patients started taking 
the study drug on the ﬁ rst day of the treatment and continued for 3 months. QOL 
was assessed using Thai Functional Assessment of Cancer Therapy-Hepatobiliary 
(FACT-HEP) and AE were assessed using Common Toxicity Criteria Adverse Events 
(CTCAE). RESULTS: There were 30 patients recruited in the study, divided into 15 
patients in each group. Baseline characteristics of the two groups were not different. 
The melatonin group had a higher but not signiﬁ cant percentage of improvement in 
FACT-Hep scores than the control in both the ﬁ rst (20% vs. 6.7%) and second (20% 
vs. 6.7%) month. Median survival was longer in the melatonin group (160 vs. 130 
days, P > 0.05). In addition, there were fewer reports of Grade 3–5 AE in the melatonin 
group than placebo in terms of anorexia (11% vs. 50%), fatigue (11% vs. 50%), 
nausea/vomiting (0% vs. 10%) and weight loss (0% vs. 20%). CONCLUSIONS: The 
combination of melatonin with standard treatment did not prolong overall survival. 
However, the melatonin treatment can decrease AE and maintain quality of life of 
non-resectable cholangiocarcinoma patients. Further studies with larger samples are 
needed. 
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OBJECTIVES: Through symptom survey in cancer patients to ﬁ nd out the symptom 
distribution and patients treatment require. Also validate set of symptom items that 
are most commonly used in Traditional Chinese Medicine (TCM). METHODS: Use 
M. D. Anderson Symptom Assessment Inventory (MDASI) that previously validated 
Chinese version. Add 10 TCM items. We also asked the questions about using TCM 
request in cancer care. A multi center cross-sectional study using a convenience sample 
of 340 patients were conducted in 3 hospitals in Beijing and Dalian. Statistical use 
Spss and Excel software. Self evaluate questioner with Cronbach’s Alpha score. 
RESULTS: The most severe symptoms were fatigue 89.4%, sleeping disturbance 
74.4%, moth drier 72.9%, and poor appetite 72.9%, forgotten 71.2%. The inﬂ uence 
of cancer symptoms to work, mood and activity were 89.7%, 82.6%, 78.6% sepa-
rately. The quality of life was affected severely. 80% patients want to regulate the 
body with TCM. Almost 100% patients hope to know the knowledge of integrated 
TCM and western medicine, and the effect of TCM treatment cancer and health 
recover. Cronbach’s Alpha score indicated acceptable internal consistency both the 
MDASI and TCM items, 0.86 for MDASI, 0.78 for TCM, 0.9 for MDASI_TCM 23 
items. CONCLUSIONS: Fatigue, sleep disturbance, moth drier, poor appetite and 
forgotten are more severe symptoms in our cancer patient’s survey. Greatly affect the 
quality of life of patients. There are an extremely request that TCM holism regulation 
in cancer patients. The MDASI and its TCM model could a critical tool to measure 
the effectiveness of TCM in cancer symptom management. 
